Lise Matton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lise Matton has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anne-Marie Ruppert
Sorbonne Université, GRC n°04, Theranoscan, AP-HP, Service de Pneumologie, Centre Expert en Oncologie Thoracique, Centre Constitutif Maladies Pulmonaire Rares, Hôpital Tenon, Paris, France
1 shared publicationAnthony Canellas
Sorbonne Université, GRC n°04, Theranoscan, AP-HP, Service de Pneumologie, Centre Expert en Oncologie Thoracique, Centre Constitutif Maladies Pulmonaire Rares, Hôpital Tenon, Paris, France
1 shared publication- Antoine Cortot
Service d'Hépato-Gastroentérologie et Registre des Maladies Inflammatoires du Tube Digestif du Nord-Ouest de la France (EPIMAD)
1 shared publication Antoine Parrot
Sorbonne Université, GRC n°04, Theranoscan, AP-HP, Service de Pneumologie, Centre Expert en Oncologie Thoracique, Centre Constitutif Maladies Pulmonaire Rares, Hôpital Tenon, Paris, France
1 shared publicationArmelle Lavolé
Sorbonne Université, GRC n°04, Theranoscan, AP-HP, Service de Pneumologie, Centre Expert en Oncologie Thoracique, Centre Constitutif Maladies Pulmonaire Rares, Hôpital Tenon, Paris, France
1 shared publication- Jacques Cadranel
Department of Pneumology, Hôpital Tenon, Assistance Publique—Hôpitaux de Paris, Sorbonne Université , Paris
1 shared publication
Latest Publications
- 1 January 2020
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 12 (1) , 46
Activité du nerf vague dans le cancer bronchopulmonaire métastatique, impact sur l’efficacité et la tolérance de l’immunothérapie
- 1 January 2020
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 12 (1) , 46
Activité du nerf vague dans le cancer bronchopulmonaire métastatique, impact sur l’efficacité et la tolérance de l’immunothérapie
- Open Access
- 9 October 2019
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 28 (153) , 190058
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (≈13%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those with advanced NSCLC. Emphasis is placed on the differences in terms of frequency or clinical picture observed depending on whether the ICI is used as monotherapy or in combination with another ICI or chemotherapy. Other pulmonary complications observed in cancer patients, yet not necessarily immune-related, are reviewed, such as sarcoid-like granulomatosis, tuberculosis or other infections. A proposal for pragmatic management, including differential diagnosis and therapeutic strategies, is presented, based on the ICI-P series reported in the literature and published guidelines.
- 9 October 2019
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 28 (153) , 190058
Open AccessPulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (≈13%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those with advanced NSCLC. Emphasis is placed on the differences in terms of frequency or clinical picture observed depending on whether the ICI is used as monotherapy or in combination with another ICI or chemotherapy. Other pulmonary complications observed in cancer patients, yet not necessarily immune-related, are reviewed, such as sarcoid-like granulomatosis, tuberculosis or other infections. A proposal for pragmatic management, including differential diagnosis and therapeutic strategies, is presented, based on the ICI-P series reported in the literature and published guidelines.